Announced
Completed
Financials
Sources
Tags
Acquisition
United States
Biotechnology
medical
Private
biotechnology
Minority
Life science
Single Bidder
Friendly
Domestic
Venture Capital
Private Equity
Completed
Synopsis
A consortium of investors, including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, 3x5 Partners, Codon Capital and Vivo Capital led a $93m Series A round in Bonum Therapeutics, a biopharmaceutical company. “We have enormous confidence in the Bonum team’s ability to advance a broad portfolio of first-in-class therapeutics through the development process. With support from this strong syndicate of new and existing investors, Bonum is well positioned to deliver on the potential of its validated platform,” Samuel Bjork, Digitalis Ventures Partner.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.